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Summary
Themost common of all activating BRAFmutations (T1799A)
leads to a substitution of valine (V) to glutamic acid (E) at the
position 600 of the amino acid sequence. The major goal of
this study was to compare detection of the BRAF V600E
mutation by DNA sequencing with immunohistochemistry
(IHC) using the anti-BRAF V600E (VE1) antibody. Archival
formalin ﬁxed, parafﬁn embedded tissues from 352 patients
with colon adenocarcinoma (n¼279) and papillary thyroid
carcinoma (n¼ 73) were evaluated for the BRAF V600E
mutation by sequencing and IHC. The discordant cases were
re-evaluated by repeat IHC, SNaPshot and next-generation
sequencing (NGS). Furthermore, the effect of pre-analytical
variables on the utility of this antibody was evaluated in two
xenograft mouse models. After resolving 15 initially discor-
dant cases, 212 cases were negative for the BRAF V600E
mutation by IHC. Of these, 210 cases (99.1%) were also
negative by sequencing and two cases (0.9%) remained
discordant. Of the 140 cases that were IHC positive for BRAF
V600E, 138 cases were conﬁrmed by sequencing (98.6%)
and two cases remained discordant (1.4%). Overall, the
negative predictive value was 99.1%, positive predictive value
98.6%, sensitivity 98.6%, speciﬁcity 99.1% and overall per-
centage agreement 98.9% (348/352 cases). Tissue ﬁxation
studies indicated that tissues should be ﬁxed for 12–24h
within 2 h of tissue collection with 10% neutral buffered for-
malin.
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INTRODUCTION
The BRAF gene, located on chromosome 7q34, encodes a
cytoplasmic serine-threonine kinase. This kinase initiates the
activation of the mitogen-activated protein kinase (MAPK)
signalling pathway.1 The oncogenic mutations in the kinase
region of BRAF gene result in constitutive activation of the
MAPK signalling pathway, leading to increased cell prolifer-
ation, resistance to apoptosis and tumour progression.1 BRAF
mutations are considered to be driver mutations and are usually
found in tumours that are wild-type for KRAS and NRAS.
The majority of the BRAF mutations occur at amino acid
V600, with the V600E mutation being most prevalent. The
BRAF V600E mutation is caused by transversion T!A at
nucleotide 1799 (T1799A) and results in a substitution of valine
(V) to glutamic acid (E) at the position 600 of the amino acid
sequence.1 Other mutations such as V600K, V600M, V600R,
V600D and V600G are less common.2 The BRAF V600E
mutation is detected in approximately 8% of all solid tumours,
including 45% of papillary thyroid carcinomas, 40–60% of
melanomas, 5–15% of colorectal adenocarcinomas, 35% of
serous low grade and borderline ovarian carcinomas, 1–3%
of non-small cell lung cancers, and 5–7% of cholangiocarci-
nomas.3,4 Furthermore, the BRAF V600E mutation is found in
100% of hairy cell leukaemia,5 54% Erdheim–Chester disease,
38% of Langerhans cell histocytoses6 and 60% of pleomorphic
xanthoastrocytomas.7 Notably, the BRAF V600E mutation is
also present in benign precursor lesions such colonic serrated
adenomas,8 suggesting that it is a common driver mutation,
with additional oncogenic events likely required for transform-
ation to malignancy or for progression from low to high tumour
grade.
The BRAF V600E mutation is an important predictive and
prognostic biomarker. The BRAF inhibitors vemurafenib and
dabrafenib both specifically target mutated BRAF at position
V600 and have been approved for use in patients with meta-
static melanoma.9,10 There is also preclinical and clinical
evidence that the BRAFV600Emutation is a negative predictor
of benefit from epidermal growth factor receptor inhibitor
therapy in advanced colorectal cancer.11 In microsatellite
unstable colorectal cancer (CRC), the BRAF V600E mutation
is typically observed in sporadic tumours and not in hereditary
non-polyposis colorectal cancer (HNPCC)/Lynch syn-
drome.11–14 In this setting, BRAF V600E mutation status is
used to triage patients for germline mismatch repair (MMR)
gene testing to differentiate MLH1-deficient sporadic colo-
rectal cancer from HNPCC/Lynch syndrome caused by
germ-lineMLH1mutations.12–14 BRAFV600Emutation status
is also an adverse prognostic biomarker in patients with stage
IV CRC, particularly those with MMR proficient tumours.15–17
In fact, Toon et al. suggested that the routine assessment of the
MMR and BRAFV600Emutational status should be performed
at the same time on all colorectal carcinomas to identify not
only the patients with Lynch syndrome in MMR deficient
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group, but also to identify the MMR proficient/BRAF V600E
group with poor prognosis.17 Additionally, the presence of
BRAF V600E mutation is also significantly associated with
increased cancer-related mortality in patients with papillary
thyroid cancer in univariate analysis but less so in multivariate
analysis.18 The BRAF V600E mutation independently predicts
central compartment lymph node metastasis and is linked with
a higher rate of tumour recurrence, tumour related mortality and
aggressiveness.19–22
A common approach for the detection of BRAF mutations is
sequencing of tumour DNA. Various DNA-based methods have
been employed, including techniques such as Sanger sequen-
cing, pyro-sequencing and high resolution melting analysis to
scan for unspecified mutations, and allele-specific methods
such as SNaPshot, designed to only detect specific mutations.
While these methods are typically able to detect a mutant allele
in a background of 5–20-fold excess of wild-type alleles, IHC
allows direct visualisation of the mutant protein in the tumour
cells at single-cell resolution.
The anti-BRAF V600E (VE1 clone) antibody is a mutation-
specific mouse monoclonal antibody that was raised against
a synthetic peptide representing the BRAF V600E mutated
amino acid sequence from amino acids 596 to 606 (GLA-
TEKSRWSG).23,24 The primary goal of this study was to
compare the performance of the anti-BRAF V600E (VE1)
antibody by IHC with DNA sequencing in patient samples of
colorectal cancer and papillary thyroid cancer. Because of the
critical importance of pre-analytical standardisation, we also
evaluated the effect of relevant variables such as fixation delay,
the use of different fixatives and the duration of fixation on the
detection of BRAF V600E expression in xenograft models.
MATERIALS AND METHODS
Cell lines and chemicals
The human A2058 melanoma cell line and LS411N colon cancer cell line were
obtained from American Type Culture Collection (ATCC; USA). Both cell lines
carry BRAF V600E mutations (http://cancer.sanger.ac.uk/cancergenome/pro-
jects/cosmic/). The A2058 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM, ATCC) supplemented with 10% fetal bovine serum
(HyClone, USA) and 1% penicillin-streptomycin (Mediatech, USA) at 378C
in 5% CO2. The LS411N cells were cultured in RPMI-1640 medium (ATCC)
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at
378C in 5% CO2. All other chemicals were of the highest purity available.
Tumour specimens
A total of 352 formalin fixed, paraffin embedded (FFPE) tissues were inves-
tigated in the present study including 279 colorectal adenocarcinoma (CRC)
cases and 73 papillary thyroid carcinoma (PTC) cases. Two hundred and thirty-
eight consecutive colon cancer samples were provided as tissue microarrays
(TMA) arranged as triplicate 1.7mm cores, whereas the 73 thyroid cancer cases
and 41 colon adenocarcinomas were provided as whole tissue sections. The
tissue samples were obtained from the Ventana Medical Systems tissue bank
(Tucson, USA), SA Pathology, (Adelaide, Australia) and St Vincent’s Hospital
(Melbourne, Australia; 27 of the thyroid cancer cases from St Vincent’s Hospital
have been previously published).22 All cases were provided in accordance with
approval granted by the institutional Human Research Ethics Committees.
Xenografts
All animal studies were conducted in accordance with the Guidance for the Care
and Use of Laboratory Animals (National Institutes of Health, Bethesda, USA)
and approved by the Institutional Animal Care and Use Committee. Two
xenograft models (A2058 melanoma and LS411N colorectal carcinoma cell
lines) were selected to evaluate potential variations in staining intensity with
different fixation conditions. A total of 10 106 A2058 cells or LS411N cells
were implanted subcutaneously into the right flank of SCID mice. When the
tumour size reached about 300 mm3, tumours were excised, divided into smaller
pieces and placed in different fixatives for various time periods or kept without
fixative (ischaemia) for 0.5–24 h as described below.
BRAF immunohistochemistry
An immunohistochemical method using the anti-BRAF V600E (VE1) antibody
was developed at Ventana Medical Systems. Sections (5mm) were cut from the
FFPE blocks. Testing was performed using the anti-BRAF V600E (VE1)
antibody (Ventana Medical Systems) on the Benchmark XT platform with Cell
Conditioning 1 for 64min, pre-peroxidase inhibition and primary antibody
incubation for 16 min at 378C. The OptiView DAB IHC Detection Kit (Ventana
Medical Systems) was used to detect BRAF V600E protein expression. Tissues
were counterstained with Hematoxylin II and Bluing Reagent for 4 min. To
measure the level of non-specific background signal, each tissue was also
stained with a mouse monoclonal antibody (MOPC-21) [Negative Control
(Monoclonal), Ventana Medical Systems]. This antibody is not directed against
any known epitope present in human tissue.
The pathologists scoring the BRAF V600E IHC were blinded to the DNA
mutation status at the time of interpretation of the IHC status. IHC was
considered positive if there was unequivocal diffuse cytoplasmic staining with
the VE1 antibody in >85% of tumour cells. The intensity of staining of BRAF
expression in tumour cells was recorded on a 0–3 scale. Strong cytoplasmic
staining was scored as 3, medium cytoplasmic staining as 2, weak cytoplasmic
staining as 1 and the absence of staining was scored as 0. Scores of 1–3
represented positive staining, while scores less than 1 were considered negative
staining. Nuclear staining in normal colonic epithelial cells and tumour cells was
sometimes observed, although the significance of this is not understood and such
cases were not considered as positive for BRAF V600E mutation.
Fixation studies
The effect of different fixatives, fixation time and delay to fixation was
evaluated in this study. Five fixation times for each of six common fixatives
were tested. The selected fixation times represent the lower and upper ranges
used in clinical histopathology practice and the selected fixatives represent
common fixatives used globally in clinical histopathology. A2058 xenografts
and LS411N xenograft tissues were fixed at room temperature for 1 h, 6 h, 12 h,
24 h and 72 h with each of the following fixatives prior to dehydration and
embedding in paraffin: 10% neutral buffered formalin (10% NBF; J. T. Baker
Chemicals, USA), zinc formalin (Anatech, USA), alcohol formalin acetic acid
(AFA; Electron Microscopy Sciences, USA), 95% alcohol, Prefer (glyoxal,
alcohol; Anatech) and Z-5 (formalin, zinc, alcohol; Anatech).
Furthermore, the effect of fixation delay (cold ischaemia) was evaluated. In
this experiment, A2058 and LS411N xenograft tissues were kept on the bench at
room temperature for 30mins, 1 h, 2 h, 6 h, and 24 h before fixation with 10%
NBF for 24 h. After fixation and processing, 5mm sections were cut from the
xenografts and stained with the anti-BRAF V600E (VE1) mouse monoclonal
antibody on the Benchmark XT platform with the same protocol used for human
tissues. Signal intensity scores (SI) were compared to a nominal reference
fixation protocol (10% NBF at room temperature for 24 h), since this is
recommended in standard practice. Due to cross-reactivity of the mouse
monoclonal VE1 antibody in mouse tissues, staining was only assessed in
the human tumour cells in the xenograft samples.
BRAF V600E sequencing
BRAF Sanger sequencing and competitive polymerase chain reaction (C-PCR)
Genomic DNA was extracted from 10–20mm thick whole tissue sections from
352 FFPE samples using the QIAamp FFPE Tissue Kit (Qiagen, USA) accord-
ing to the manufacturer’s instructions. Tissue from the same tumour block was
used for both DNA extraction and the BRAF V600E IHC on all cases. Mutation
analysis was initially performed on macrodissected tumour tissue by dideoxy
(Sanger) sequencing for all cases except for 27 papillary thyroid cancer cases
from St Vincent’s Hospital, which were tested by C-PCR using the Seeplex
BRAF V600E ACE Detection Kit (Seegene, South Korea) as previously
described.22 Sanger sequencing primers were designed to amplify the region
of exon 15 containing the V600 nucleotide. Three sets of primers were used
including: (1) BRAF-ex15F-TGCTTGCTCTGATAGGAAAATG, BRAF-
ex15R-AGCATCTCAGGGCCAAAAAT; (2) BRAF-ex15F-ATGCTTGCTCT
GATAGGAAA, BRAF-ex15R-TGGATCCAGACAACTGTTCA; and (3)
BRAF-ex15F-TTCATAATGCTTGCTCTGATAGG; BRAF-ex15R-AGTAAC
TCAGCAGCATCTCAGG. These generated product sizes of 226 bp, 166 bp and
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246 bp, respectively. Both forward and reverse strands were sequenced on an
Applied Biosystems 3730xl DNAAnalyzer or ABI3130xl Genetic Analyzer and
analysed using Sequence Scanner v1.0 software (Applied Biosystems, USA) or
GeneMapper v4 software (Applied Biosystems).
BRAF SNaPshot assay
The region encompassing nucleotides 1798, 1799 and 1800 of the BRAF gene
was amplified by polymerase chain reaction (PCR) using the third primer pair
described above and the presence of a mutation was detected using a commer-
cially available SNaPshot kit (Life Technologies, USA). A detection primer
[BRAF-600DET- (C)5TGATTTTGGTCTAGCTACAG] with non-specific 5
0
sequences was specifically designed to hybridise immediately adjacent to the
mutation sites and to give different fragment lengths so that the various
mutations would be separated. The primer was hybridised to the PCR product
and a primer extension reaction incorporating all four fluorescently labelled
dideoxynucleotides allowed the nucleotides at positions 1798, 1799 and 1800 to
be determined after analysing the labelled products on an ABI PRISM 3130xl
genetic analyser (Applied Biosystems). An estimate of mutation load (sensi-
tivity) was determined by measuring the area under the mutant peak and
comparing to the wild-type peak.
Next generation sequencing
Deep sequencing of the region of BRAF exon 15 containing the V600 locus was
performed with a customised targeted next generation sequencing (NGS)
method. To ensure diverse coverage of the exon, 100 ng of DNA was amplified
with the following three pairs of primers to amplify 210 bp amplicons: BRAF-
V600 F1 - CTACACCTCAGATATATTTCTT, BRAF-V600 R1 - TTCTTACC
ATCCACAAAATGG; BRAF-V600 F2 - TACACCTCAGATATATTTCTTC,
BRAF-V600 R2 - CCTCAATTCTTACCATCCAC; BRAF-V600 F3 - ACCTC
AGATATATTTCTTCATG, BRAF-V600 R3 - AGCCTCAATTCTTACC
ATCC. A second round amplification used Illumina Truseq primer-adapters
(Illlumina, USA) to add dual bar codes and produced 270 bp fragments for
sequencing. The bar coded amplicons were multiplexed into a single pool and
were sequenced using the 2 150 bp configuration on an Illumina MiSeq as per
the manufacturer’s instructions. The FASTQ files were imported into CLC
Genomics Server 5.5.2 (CLC Bio, Denmark), trimmed and mapped against the
reference sequence (NG_007873) for the human BRAF gene exon 15.
Statistical analysis
The overall percent agreement (OPA) rate between IHC using the anti-BRAF
V600E (VE1) antibody and sequencing was calculated as the total number of
concordant cases divided by the total number of evaluated cases. Assuming that
DNA sequencing is the gold standard for the detection of the BRAF V600E
mutation, sensitivity was calculated as a proportion of the positive cases which
were correctly identified by IHC among all positive cases in DNA sequencing.
Specificity was calculated as the proportion of negatives cases which are
correctly identified by IHC among all negative cases in DNA sequencing.
Negative predictive value was calculated as a proportion of negative cases
correctly diagnosed as negative for BRAF V600E mutation by IHC. Positive
predictive value was calculated as a proportion of positive cases correctly
diagnosed as negative for BRAF V600E mutation by IHC. Analyses were
performed using SAS version 9.3 software (SAS, USA).
RESULTS
Anti-BRAF V600E (VE1) immunohistochemistry
All 352 cases were examined for presence of BRAF V600E
mutation by IHC using the anti-BRAF V600E (VE1) antibody
on the automated Ventana Benchmark XT platform. Initially,
143 cases were positive (89 CRC and 54 PTC) and 209 cases
were negative (190 CRC and 19 PTC) for BRAF V600E
expression. Representative images are shown in Fig. 1.
Of these 352 cases, 15 cases were discordant with the initial
Sanger sequencing results. For the 10 discordant cases, repeat
IHC confirmed the initial positive IHC results in five cases
(3 CRC, 2 PTC) and the initial negative IHC results in five
cases (2 CRC, 3 PTC).
Of the five remaining discordant cases, repeat IHC resolved
two PTC cases (whole tissue sections), both 1þ, which were
re-scored 0. Since no staining was detected in these tissues,
repeat sequencing was not required. Two CRC cases from
TMAs initially scored as 1þ were re-scored as 0 after repeat
IHC on a whole tissue section. In one case, high background
staining was observed including cytoplasmic staining of the
normal colonic mucosa. In the other case, all three TMA cores
originated from a focal area of 1þ staining occupying10% of
an otherwise negative tumour. One CRC case initially scored as
0 on all three TMA cores was rescored as 2þ when IHC was
repeated on the whole tissue section. The three tissue cores
from this case had all been selected from a negative area within
a heterogeneously stained tumour. These data suggest that the
discordance between the two IHC assays was the result of
sampling bias. All these three TMA cases were re-sequenced
using DNA from whole tissue sections to confirm the BRAF
mutation status. Overall, IHC discrepancies between whole
tissue sections and TMAs occurred in three of 238 TMAs.
In summary, following repeat IHC to resolve discrepancies,
five cases were re-scored (4 cases from 1þ to 0, 1 case from 0 to
2þ), 140 cases were confirmed to be positive by IHC (88 CRC
and 52 PTC) and 212 cases were confirmed to be negative by
IHC (191 CRC and 21 PTC).
DNA sequencing
A total of 325 cases were examined for presence of the BRAF
V600Emutation by Sanger sequencing and 27 cases by C-PCR.
Initially, 140 cases were positive (87 CRC and 53 PTC) and 212
cases were negative (192 CRC and 20 PTC) for the BRAF
c.T1799A mutation. No mutations other than BRAF c.T1799A
were detected. Representative images are shown in Fig. 2.
Sanger sequencing was repeated and BRAF SNaPshot and/or
NGS were performed on DNA extracted from whole tissue
sections from the 13 cases that were discordant with the IHC
results. There was perfect concordance between the repeat
Sanger sequencing and SNaPshot results. Of these 13 cases,
the initial BRAF c.T1799A mutation was confirmed in two
cases and the initial wild-type (WT) status confirmed in three
cases. Four cases (3 CRC and 1 PTC) that were initially
c.T1799A mutant were found to be WT by repeated Sanger
and SNaPshot sequencing and four cases (2 CRC and 2 PTC)
that were initially WT were found to contain c.T1799A
mutations. Four initially discordant cases had non-amplifiable
DNA and could not be resequenced by repeated Sanger and
SNaPshot sequencing. Next generation sequencing, amplifying
shorter amplicons than Sanger sequencing, resolved these non-
amplifiable cases.
Overall, 140 cases (86 CRC and 54 PTC) were positive for
the BRAF cT1799A mutation and 212 cases were WT (193
CRC and 19 PTC). Although the reasons for the four false
positive initial Sanger sequencing results are not known, in two
cases the reported allele frequencies were 5% and 9%, well
below the level of detection for Sanger sequencing, suggesting
these were interpretation errors. Likewise, the reasons for the
two false negative Sanger sequencing results are not known but
likely the result of low tumour purity or insufficient tumour
cells for DNA extraction.
DNA sequencing and IHC concordance
Overall, out of the 15 initially discordant cases, 11 cases were
resolved by repeating the IHC using whole tissue slides and/or
by sequencing using more sensitive methods. These measures
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effectively overcame analytical errors due to heterogeneously
stained tumours and low tumour purity.
However, there were four residual discordant cases that
could not be resolved with the methods and tissue samples
available. Two CRC cases were clearly BRAF V600E positive
by IHC (2þ in 85% and 100% of tumour cells) with no BRAF
c.T1799A mutation detected by SNaPshot or NGS, which have
limits of detection of 3% and 1%, respectively. These were
regarded as IHC false positives. Two PTC cases were clearly
negative by IHC on three different occasions but both had
BRAF c.T1799A mutations detected by Sanger sequencing and
NGS. These were regarded as IHC false negatives.
In summary, assuming the sequence status is the gold
standard, the IHC assay using the anti-BRAF V600E (VE1)
antibody had 98.6% positive predictive value, 99.1% negative
predictive value, 98.6% sensitivity, and 99.1% specificity.
The overall percentage agreement across all cases was
98.9% (348/352 cases). The summary of the data is shown
in Tables 1 and 2.
The effect of ﬁxation conditions
The results from the fixation studies clearly show that fixation
with 10% neutral buffered formalin (NBF) for 12, 24 or 72 h are
the optimal fixation conditions for immunohistochemical deter-
mination of the BRAFV600Emutation using the BRAFV600E
(VE1) antibody (Table 3). Fixation with 10% NBF for less than
12 h resulted in a weaker BRAF V600E signal compared to
longer fixation times (12–72 h) in our xenograft models.
Fixation with zinc formalin for less than 12 h or more than
72 h resulted in weaker signal and a granular staining pattern
compared to recommended fixation times (12–24 h). When the
xenograft tissues were fixed with other fixatives such as 95%
EtOH, Z-5, AFA, or Prefer, the BRAF V600E staining was
significantly compromised compared to 10% NBF for 12 and













Fig. 1 Representative images of colon cancer and thyroid cancer tissues positive/negative for BRAF V600E mutation stained with the anti-BRAF V600E (VE1) mouse
monoclonal antibody, negative mouse monoclonal control and H&E. Scale bar¼ 200mm.
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24 h, regardless of fixation time (Table 3). In addition, atypical
staining patterns were observed in the cytoplasm of the xeno-
graft tissues fixed with Prefer and Z-5 (granular or membranous
staining pattern, Table 3). Staining was weak in the tissues
fixed with AFA and no staining was detected in the tissues fixed
with 95% EtOH. These results were consistent in both xeno-
graft models.
The effect of delayed fixation on BRAF V600E expression
was also studied. Xenograft tissues were left on the bench at
room temperature for various time periods prior to fixation with
10% NBF for 24 h (Table 4). The results from this study show
that the intensity of BRAF V600E protein staining is not
significantly degraded after a fixation delay of up to 2 h in
LS411N and A2058 xenografts. However, the A2058 xeno-
grafts showed abnormal membranous staining after a 6 h delay
in fixation and the LS411N xenografts showed patchy staining
after 24 h of delay to fixation.
In summary, these data suggest that 95% EtOH, AFA, Z-5
and Prefer should not be used as fixatives for anti-BRAF
V600E (VE1) immunohistochemistry. In addition, tissues
should be fixed within 2 h following tissue collection.
DISCUSSION
Oncogenic mutations in the BRAF gene are considered driver
mutations in a variety of human cancers such as thyroid cancer,
melanoma, colon cancer, ovarian cancer, non-small-cell lung
cancer and hairy cell leukaemia. More than 70 different
mutations in the BRAF gene have been identified; however,
the most prevalent mutation is the V600E mutation, in which
BRAF V600E +  colon cancer BRAF V600E – colon cancer 
80 85 85 90
A B
Fig. 2 Mutation analysis of BRAF gene in colon cancer tissues. Example of sequencing electropherogram with BRAF codon wild-type (A) and V600E heterozygous
(B). The corresponding images of tissues stained with anti-BRAF V600E (VE1) mouse monoclonal antibody are included. Brown colour indicates positive staining with
anti-BRAF V600E (VE1) antibody.
Table 1 Summary of the results of the BRAF V600E mutation status in colon cancer (n¼ 279) and thyroid papillary carcinoma (n¼ 73) cases
BRAF V600E results BRAF V600E sequence positive BRAF V600E sequence negative Total
Initial results*
IHC positive 134 9 143
IHC negative 6 203 209
Total 140 212 352
Final results{
IHC positive 138 2 140
IHC negative 2 210 212
Total 140 212 352
* Initial IHC using whole tissue section (n¼ 114) and TMAs (n¼ 238) and DNA sequencing [Sanger sequencing (n¼ 325), C-PCR (n¼ 27)].
{ Final sequencing data for all cases [IHC on whole tissue sections (n¼ 120) and TMAs (n¼ 238); DNA sequencing - Sanger sequencing (n¼ 325), C-PCR
(n¼ 27), SNaPshot (n¼ 9), next generation sequencing (n¼ 13)].
IHC, immunohistochemistry; TMAs, tissue microarrays.
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thymine is substituted with adenine at nucleotide 1799.25 This
leads to replacement of valine (V) for glutamate (E) at position
600 of the amino acid sequence. BRAF V600E mutated cancers
are generally more aggressive and are associated with poorer
prognosis.26 Therefore, BRAF V600E is an attractive thera-
peutic target with several small molecule inhibitors either on
the market or in clinical development.
Given the clinical importance of detecting the BRAF V600
mutations in human tumour samples, there is a critical need for
V600-specific assays that are accurate, robust, easy to use and
interpret, widely available and affordable. The Cobas 4800
BRAF Mutation Test (Roche Molecular Diagnostics, USA) is
approved by the United States Food and Drug Administration
as an in vitro diagnostic device for use as an aid in selecting
patients with advanced or metastatic melanoma and papillary
thyroid carcinoma whose tumours harbour the BRAF V600E
mutation. This assay is more sensitive than Sanger sequencing
and can detect V600E mutations at >5% allele frequency in
FFPE tissues.27,28 However, there is currently no approved
assay for the detection of BRAF mutations in other tumour
types that harbour the V600E mutation. While various methods
have been devised including Sanger sequencing, pyrosequen-
cing, high resolution melt analysis and SNaPshot analysis,
these techniques require tumour tissue to be sent to a molecular
pathology laboratory for analysis, are dependent upon having
high quality DNA, and require a sufficient proportion of tumour
cells compared to wild-type cells in the sample. In contrast to
molecular testing, IHC is routinely available in most anatom-
ical pathology laboratories, is cheaper than all current sequen-
cing methods, has a rapid turn-around time, and is not
dependent upon DNA quality or proportion of tumour cells
in a sample. Furthermore, IHC allows in situ assessment of the
level of expression of the mutant protein within the tumour cells
at single cell resolution, providing confidence that correct
cellular elements have been assessed.
In this paper we present one of largest validation studies
regarding the detection of the BRAFV600Emutation in thyroid
and colon cancer samples using immunohistochemistry with
the anti-BRAF V600E (VE1) mouse monoclonal antibody.
Based on initial IHC and Sanger sequencing results, there
was high concordance with sequencing with an overall percen-
tage disagreement across all cases of 4.26% (15/352 cases).
Eleven of the 15 initially discordant cases were resolved by
repeat IHC (4 cases), repeat Sanger sequencing (5 cases) or
NGS (2 cases). There were four residual discordant cases that
could not be resolved with the methods employed and remain-
ing available tissue samples. Assuming DNA sequencing is the
gold standard, there were two IHC false positives (both CRC)
and two IHC false negatives (both PTC).
Two cases in our cohort were negative by IHC but positive
by sequencing. Such IHC false negative results probably arise
Table 2 Sensitivity, speciﬁcity, predictive values and overall agreement for
determination of the BRAF V600E mutation status using IHC and DNA
sequencing in colon cancer and thyroid papillary carcinoma after initial





Sensitivity (%) 95.7 98.6
Speciﬁcity (%) 95.8 99.1
Negative predictive value (%) 97.1 99.1
Positive predictive value (%) 93.7 98.6
Overall agreement (%) 95.7 98.9
Table 3 BRAF V600E signal intensity scores (SI) for A2058 and LS411N xenografts ﬁxed using different ﬁxatives for various time-points
Fixative






































1 0.5 2 0.5 0.5 0 0 0 0 0.5 0 1 1
6 2 2.5 1* 1 0 0 1 1 2 2 2 1.5*
12{ 3 3 2* 2* 0 0 1 1 3 3 1z 1.5*
24{ 3 3 2* 2* 0 0 0.5 0 3 3 1.5 2*
72 3 3 2.5* 2* 0 0 0.5 1 2* 2.5 1.5 2*
A2058 and LS411N xenografts were ﬁxed at room temperature for 1, 6, 12, 24 or 72 h with different ﬁxatives and stained with anti-BRAF V600E (VE1) antibody on a
BenchMark XT.
* Granular staining pattern.
{Gold standard.
zAbnormal signal distribution (membranous).
AFA, alcohol formalin acetic acid; NBF, neutral buffered formalin.
Table 4 BRAF V600E staining intensity scores for A2058 and LS411N




0 h 3 3
1 h 3 3
2 h 3 3
6 h 3 2*
24 h 2.5 2.5
A2058 and LS411N xenografts were left on the bench at room temperature for
0.5, 1, 2, 6, or 24 h prior to ﬁxation in 10% NBF for 24 h. The xenograft tissues
were stained with anti-BRAF V600E (VE1) antibody on a BenchMark XT.
* Abnormal signal distribution (membranous).
NBF, neutral buffered formalin.
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from the loss of expression of the mutant antigen. Tissue
ischaemia, for example in areas surrounding necrotic areas,
has been shown to reduce BRAF V600E protein expression and
is a potential source of false negative IHC results, particularly
on small biopsies of metastatic tumours.23 It is also possible
that additional mutations may prevent translation of the mRNA
into the functional protein. Another reason for the lack of
staining or heterogeneous staining could be due to suboptimal
fixation conditions. Using two different xenograft models, we
have shown that optimal detection of the BRAF V600E mutant
3
LS411N 
10% NBF 95% EtOH Prefer
10% NBF 95% EtOH Prefer
Zn-formalin Z-5 fixative AFA
Zn-formalin Z-5 fixative AFA
A2058
Fig. 3 Representative images of LS411N and A2058 xenograft tissues stained with anti-BRAF V600E (VE1) mouse monoclonal antibody after ﬁxation with different
ﬁxatives for 24 h. Scale bar¼ 200mm.
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protein by immunohistochemistry requires optimal tissue fix-
ation with 10% neutral buffered formalin (NBF) for 12–24 h
within 2 h of tissue collection. Other fixatives, fixation for less
than 6 h or more than 72 h, or delay in fixation for more than 6 h
may negatively affect the staining pattern and signal intensity
of BRAF V600E (Tables 3 and 4). Significantly decreased or
absent staining in a known BRAF V600E mutant cell line was
found in the samples from two xenograft models fixed with
inappropriate fixative solutions (Fig. 3). This highlights the
importance of correct fixation procedures in clinical practice.
Two of our cases were positive by IHC but negative by
sequencing. Such IHC false positives are more difficult to
explain. It is likely that tumours with uniform, unequivocal
staining with the anti-BRAF V600E (VE1) antibody in reality
represent BRAF c.T1799A mutant tumours and false negative
sequencing results rather than false positive IHC results. This
arises not infrequently with Sanger sequencing due to an excess
of wild type allele compared to the mutant allele when only the
minority of cells in the sample submitted for sequencing are
from tumour areas. Such false negative sequencing results can
be avoided by using more sensitive or allele-specific methods.
However, as shown in our cases, even deep sequencing using
NGS did not detect a mutation in DNA extracted from the
sample.
The anti-BRAF V600E (VE1) antibody provided the correct
result compared to Sanger sequencing in 337 of 352 cases in our
series (95.7% agreement). However, our series was confounded
by TMA sampling bias in molecularly heterogeneous tumour
samples and by the known insensitivity of Sanger sequencing.
When these discordant cases were re-tested using whole tissue
sections and/or more sensitive sequencing methods, the anti-
BRAF V600E (VE1) antibody gave the correct result in 348 of
352 cases (98.9% agreement). The latter figure is likely to more
faithfully reflect clinical practice. This study demonstrates that
IHC using the anti-BRAF V600E (VE1) antibody with the
VENTANA OptiView DAB Detection system and BenchMark
XT platform is a highly specific and sensitive method for the
detection of BRAFV600E in colon cancer and papillary thyroid
carcinoma (Tables 1 and 2).
Our data are in general agreement with other studies
evaluating the anti-BRAF V600E (VE1) antibody in colon
cancer12–14,29–32 and papillary thyroid cancer.24,33–35 Six of
these 11 published studies showed 100% sensitivity and speci-
ficity when compared to DNA-based methods.14,24,30–32,35
Of the five remaining studies, four showed specificity and
sensitivity in the range of 90–99% and 89–96%, respectively.
One study was a clear outlier with a sensitivity of 71% and
specificity of 74%.29 While the majority of the published
studies12–14,24,30–32,34,35 used automated immunostainers
(Ventana Benchmark XT, ULTRA or NexES, Leica Bond
Max) and either no retrieval or alkaline retrieval, the study
by Adackapara et al. used a manual method and acidic retrie-
val.29 Therefore, it is most likely that methodological differ-
ences used in that study were responsible for the anomalous
results.
Interpretation of anti-BRAF V600E (VE1) immunohisto-
chemical staining was straightforward in the majority of cases.
The staining was exclusively cytoplasmic and present
uniformly throughout the tumour. The staining intensity was
moderate to strong and occasionally weak, but it was invariably
above background levels. Faint weak staining, any type of
isolated nuclear staining, weak staining of single interspersed
cells, or staining of monocytes or macrophages were scored as
negative. Unexplained staining was sometimes seen in the
smooth muscle and nuclei of normal epithelial cells.13,14,29,30
This staining should not be confused with positive cytoplasmic
staining of tumour cells.
Importantly, IHC with the anti-BRAF V600E (VE1) anti-
body should be validated in different tumour types. Recent
studies indicate that even strong positive immunostaining with
the anti-BRAF V600E (VE1) antibody in pituitary adenoma
does not indicate the presence of BRAF V600E mutation.36,37
Furthermore, because the antibody does not detect the V600K,
V600R, V600D or V600M mutations, the anti-BRAF V600E
(VE1) antibody should be used with caution in cancers that may
harbour different V600 mutations than V600E, such as mela-
noma, where such mutations can comprise up to 30% of all
V600 mutations.2,38,39
In summary, the results from this study demonstrated high
concordance between DNA sequencing and IHC using the anti-
BRAF V600E (VE1) antibody for detection of the BRAF
V600E mutation in colorectal cancer and papillary thyroid
cancer in FFPE tissues. In addition, we have shown that the
appropriate tissue fixation protocol is critical for the evaluation
of BRAF V600E mutation status by immunohistochemistry.
Importantly, these data suggest that IHC with the anti-BRAF
V600E (VE1) antibody performed on the Benchmark XT
automated immunostainer is a highly sensitive and specific
detection method for determination of BRAF V600E mutation
status. Advantages of this novel method include (1) high
analytical sensitivity due to single cell resolution, (2) robust
performance when the manufacturer’s instructions are fol-
lowed, (3) ease and consistency of interpretation, (4) wide-
spread availability, (5) rapid turn-around time, (6) low assay
failure rate, and (7) lower cost than DNA sequencing.
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